| 发明名称 |
Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| 摘要 |
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract. |
| 申请公布号 |
US8815838(B2) |
申请公布日期 |
2014.08.26 |
| 申请号 |
US200912574680 |
申请日期 |
2009.10.06 |
| 申请人 |
|
发明人 |
Griffith David C.;Dudley Michael N.;Surber Mark W.;Bostian Keith A.;Rodny Olga |
| 分类号 |
A61K31/397;A61K31/535;A61P11/06;A61K31/47;A61K47/02;A61K31/4375;A61K31/538;A61K9/00 |
主分类号 |
A61K31/397 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for treating a pulmonary infection, comprising administering to a human having said pulmonary infection an aerosol of a solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation to achieve a maximum lung sputum concentration (Cmax) of at least 1200 mg/L and a lung sputum area under the curve (AUC) of at least 1500 h·mg/L, wherein the solution comprises a divalent or trivalent cation concentration from about 50 mM to about 400 mM, and a levofloxacin or ofloxacin concentration from between about 50 mg/ml to about 200 mg/ml. |
| 地址 |
|
